Date: 2012-07-31
Type of information: Development agreement
Compound: EB66® cell line
Company: Vivalis (France) undisclosed party utilizing Vivalis’ proprietary EB66® cell line
Therapeutic area: undisclosed
Type agreement: developement
Action mechanism:
Disease: undisclosed
Details: Vivalis has signed a new cell line development agreement with an undisclosed party utilizing Vivalis’ proprietary EB66® cell line. This contract represents a new application of EB66® cells to create a complementing cell line for a replication-defective, virus-based vaccine candidate for human use. Terms of the agreement were not disclosed.
Financial terms:
Latest news:
